bioAffinity wins Hong Kong patent for CyPath Lung cancer diagnostic technology - BIAF News | RalliesbioAffinity wins Hong Kong patent for CyPath Lung cancer diagnostic technology
B
BIAF• Hong Kong patent strengthens CyPath Lung IP
- bioAffinity Technologies won a Hong Kong patent covering its CyPath Lung platform for noninvasive lung cancer risk assessment from sputum samples.
- Protection in Hong Kong follows a China patent granted in 2025, strengthening the company’s intellectual property position for an Asia expansion.
- The patent covers use of fluorescent markers with flow cytometry to identify cell populations linked to lung cancer in sputum.
- Management cited Asia’s roughly 1.6 million new lung cancer cases a year as a key commercial driver for the test.
•
